Drug Trial Radar · NCT04981561
Safety and Tolerability of Zelquistinel in Normal Human Volunteers
Last checked: Nov 19, 2026Latest source record: Mar 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
68
Actual
Start
Dec 9, 2016
Primary completion
Dec 21, 2017
Study completion Dec 21, 2017
Sponsor
- Lead sponsor
- Syndeio Biosciences, IncIndustry
- Sponsor type
- Industry
- First posted
- Jul 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate the safety and tolerability of single ascending doses of zelquistinel in normal human volunteers
Conditions
- Major Depressive Disorder
Interventions
zelquistinelDrug
Single dose of zelquistinel
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment emergent adverse eventsTime frame: 28 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.